MGRX vs QUCY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MGRX exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a catastrophic operating margin of -1576.40%. Despite a low Price-to-Book ratio of 0.35, the company is experiencing consistent revenue contraction (-10.30% YoY) and massive long-term value destruction, with a 5-year price decline of 99.3%. The lack of analyst coverage and bearish insider activity further signal a lack of confidence in the company's viability.
QUCY exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a critical liquidity crisis evidenced by a Current Ratio of 0.50. The company is suffering from catastrophic operational inefficiency with an operating margin of -2159.86% and a massive ROE of -488.32%. Despite beating negative earnings estimates, the fundamental trend is one of collapse, with revenue declining by 32.90% YoY and a 5-year price depreciation of 98.2%. The combination of high leverage (Debt/Equity 4.01) and shrinking revenues suggests a high risk of insolvency.
Compare Another Pair
Related Comparisons
MGRX vs QUCY: Head-to-Head Comparison
This page compares Mangoceuticals, Inc. (MGRX) and Mainz Biomed N.V. (QUCY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.